Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of autoimmune and central nervous system diseases, announces that it will present at the Maxim Group Growth Conference on Tuesday, October 7, at 9:30 a.m.

Pipex Pharmaceuticals has acquired an oral, once-daily candidate which has completed a 160-patient, multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial for the treatment of rheumatoid arthritis.

Pipex Pharmaceuticals, Inc.

Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system (CNS) and autoimmune diseases, today announced its clinical update and results for its second quarter of 2008.

Pipex Pharmaceuticals, Inc.